

CS Pharmaceuticals announces appointment of Professor Andrew Wilks as Non Executive Director

London, England, June 22, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the appointment of Professor Andrew Wilks as Non Executive Director.

Prof Andrew Wilks is a serial entrepreneur with 20 years commercial experience, following a successful academic career at the Ludwig Institute for Cancer Research. Andrew has discovered and named many novel protein kinases, including the JAK family of kinases, and went on to found ASX-listed biotech Cytopia in 1997. Since then, Andrew has founded or co-founded ten drug discovery companies. He is co-founder of the SYNthesis Group, and played a key role in building the SYNthesis med chem (Hong Kong) business which was sold to Viva Biotech in 2020. He is an elected Fellow of the Australian Academy of Science, The Australian Academy of Technology and Engineering, and the Australian Academy of Health and Medical Sciences. “We are very honoured to welcome Professor Wilks to the Board”, said Darren Mercer CEO of CSP. “Andrew’s deep knowledge of drug development, his experience as a serial entrepreneur and expertise in China will be a great asset to CSP as we build our portfolio of products.”

“I am deeply impressed by the Team at CSP and the innovative business model bringing Western rare disease and speciality medicines to China”, said Prof. Wilks. “I am convinced the changes to the regulatory landscape in China including acceptance of foreign trial data and the recent implementation of a China Orange Book means that CSP is entering the market at the optimal time. I am looking forward to working with the Team to identify appropriate assets to bring to China”.

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691